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Abstract The use of supra-physiological, exogenous cortico-
steroids in pregnancy may lead to neonatal adrenal suppres-
sion.We report on a single-center, case series study carried out
between 2006 and 2014, which included all newborns (n = 16)
of mothers using prednisolone ≥10 mg/day during pregnancy.
Newborns were routinely assessed according to hospital pro-
tocol, with follow-up until 6 weeks after birth.We investigated
the clinical symptoms and biochemical findings of adrenal
suppression occurring in the newborns. Mean dose of mater-
nal prednisolone was 29.7 ± 16.1 mg/day with a mean dura-
tion of 18.4 ± 15.4 weeks. Five newborns showed hypoglyce-
mia with normal serum cortisol concentrations and urinary
steroid profiles. Two newborns had abnormal urinary steroid
profiles, probably the result of prematurity, but with adequate
adrenal stress response during clinical sepsis.
Conclusion: In this retrospective case series, we found no
evidence of prolonged effects of maternal prednisolone use
during pregnancy on the neonatal hypothalamic-pituitary-
adrenal axis.
What is known:
• The use of prednisolone during pregnancy may cause increased
steroid levels in the fetus by partially passing through the placenta.
• So far, there was very limited data available on the occurrence of
adrenal suppression in the newborn of mothers using prednisolone
during pregnancy.
What is new:
• The use of high-dosage prednisolone during pregnancy for ≥1 week
(mean duration of 18.4 ± 15.4 weeks), prior to delivery, appears to
have little influence on the neonatal hypothalamic-pituitary-adrenal
axis.
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Introduction
Reproduction in women with serious medical problems,
such as chronic inflammatory bowel disease or asthma,
has become increasingly common. The associated use of
medication, including systemic corticosteroids, in preg-
nant women may incur an increased risk for the fetus or
newborn baby.
Prednisolone is the drug of choice as the estimated
fetal level is only 10% of the maternal level [6]. This is
the result of the conversion of prednisolone to less active
metabolites by the enzyme 11β-hydroxysteroid dehydro-
genase-2 (11-beta-HSD2) in the placenta [6]. There is less
wide experience with the use of hydrocortisone during
pregnancy. Dexamethasone is only partially metabolized
by the enzyme 11-beta-HSD2, and up to 50% reaches the
fetus [6]. When taken in high doses and over a longer
period of time, prednisolone can saturate the placental
enzymes, after which, larger amounts of corticosteroids
will cross the placental barrier [1].
Chronic use of corticosteroids may result in suppres-
sive effects on the neonatal hypothalamic-pituitary-
adrenal (HPA) axis [8]. Then, in times of physical stress,
such as an infection, the adrenal gland may not be able to
produce sufficient hormone (cortisol) to help the newborn
to respond adequately. The lack of this response
(Addisonian crisis) is a life-threatening situation for
which supplementation of corticosteroids is needed.
So far, there was no clinical data on the risk of HPA
axis suppression in newborns whose mothers had been
using systemic corticosteroids for a longer period during
pregnancy. Neither were there any studies on the influ-
ence of dosage and duration of maternal prednisolone
use during pregnancy. Local guidelines for monitoring
HPA axis suppression in newborns were therefore devel-
oped in the UMCG, covering admission to the pediatric
ward or neonatal intensive care unit (NICU), assessment
of blood pressure, blood glucose levels, serum cortisol
and plasma adrenocorticotropic hormone (ACTH) levels,
urinary steroid profile (USP), and, if necessary, dynamic
testing of the HPA axis. These measures lead to a
distressing separation of mother and child and pose a sub-
stantial financial burden on the healthcare budget. Based
on the current pathophysiological knowledge, we would
expect a substantial number of cases to show HPA axis
suppression. However, our clinical experience is that its
prevalence, and that of refractory hypoglycemia and hy-
potension, is very low.
Our aim was to determine the clinical symptoms and
biochemical signs of HPA axis suppression occurring in




We included all live-born infants whose mothers had used
≥10 mg/day of prednisolone (orally or intravenously) during
≥1 week prior to delivery, born in an 8-year period between
October 2006 and October 2014 in the University Medical
Center Groningen (UMCG). The UMCG is a tertiary hospital
with about 1600 deliveries per year, and it is the only hospital
in the region with a NICU. In the region covered by our hos-
pital, all obstetricians and midwives must consult a neonatol-
ogist and pediatric endocrinologist if they treat a pregnant
woman using systemic corticosteroids for a longer period of
time and/or prior to delivery.
Data collection
Maternal and pediatric data were collected retrospectively
from medical files.
Guideline procedures
The neonatologist is consulted for every live-born infant of
mothers who used prednisolone prior to delivery. For mothers
who used ≥10 mg/day of prednisolone, their newborn was
admitted to the maternity ward. The child was admitted to
the NICU for 48 h observation if the mother used ≥35 mg/
day of prednisolone. All newborns were routinely assessed by
physical examination and laboratory tests during their first
48 h. Dynamic testing of the HPA axis was considered only
in cases of persistent findings of adrenal suppression.
Newborns were followed up until 6 weeks after birth.
Definition of outcome measures
Blood pressurewas measured (by full-automatic oscillometric
measurement device), during the first 48 h of life and, after
48 h, when clinically indicated. Hypotension was defined as a
mean blood pressure in mmHg below the tenth percentile for
gestational and postnatal age.
Serum glucose level was measured by an enzymatic meth-
od (hexokinase-mediated reaction, Roche Modular,
Mannheim, Germany) and assessed in all newborns, every
3 h for their first 48 h. Samples were taken before oral feed-
ings. Hypoglycemia was defined as a blood glucose concen-
tration <2.6 mmol/L (46 mg/dL).
Serum cortisol and plasma ACTH level was assessed in all
newborns within the first 48 h. Ethylenediaminetetraacetic
acid (EDTA) tubes were used to collect blood samples for
ACTH, which were placed on ice and, after centrifugation,
frozen immediately until analysis. The analysis was per-
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formed by electrochemiluminescence immunoassay using
Cobas 6000 E601 (Roche Diagnostics, intra-assay coefficient
of variation (CV) 0.6–3.6% and inter-assay CV 3.5–5.4%).
Plasma cortisol was analyzed by electrochemiluminescence
immunoassay using Modular E170 (Roche Diagnostics,
inter-assay CV 2.3–4.0%). As newborns do not have a circa-
dian rhythm of cortisol secretion, samples were taken at ran-
dom moments during the day [4]. In screening adrenal dys-
function, a combined measurement of ACTH and cortisol in
blood is used as standard practice at the UMCG. Adrenal
dysfunction was defined if the ACTH level was >45.5 ng/L
(10 pmol/L) and/or the cortisol level was <200 nmol/L in full-
term newborns or 100 nmol/L in pre-term newborns. These
cutoff levels have been used for many years as institutional
reference ranges in clinical practice at the UMCG and are in
accordance with the literature [7, 9].
Urinary steroid profile (USP) was assessed in all newborns
in the first 48 h by taking a sample from a urine collection bag
[2]. After enzymatic hydrolysis of urine samples, steroids
were extracted and derivatized. Derivatized samples were an-
alyzed using quantitative gas chromatography/mass spectrom-
etry (GC/MS) with capillary chromatography. If fetal metab-
olites were absent, the USP was defined as abnormal and
repeated after 2–4 weeks.
Results
Patient population
We enrolled 16 newborns in the study. Newborn and maternal
characteristics are described in Table 1. Gestational age varied
from 26 2/7 to 41 3/7 weeks (mean 34 5/7 ± 4 4/7 weeks) and
birth weight varied from 885 to 4175 g (mean 2477 ± 1002 g).
The dose and duration of prednisolone use varied from 10 to
60 mg/day (mean 29.7 ± 16.1 mg/day) and from one to
40 weeks (mean 18.4 ± 15.4 weeks) prior to delivery.
Outcome
Five newborns had transient hypoglycemia (Table 1). They all
showed well-known risk factors for hypoglycemia (prematu-
rity (n = 3), birth weight large for gestational age (n = 1), and
maternal insulin-dependent diabetes gravidarum (n = 1)).
They received extra oral feedings and/or intravenous glucose
administration according to the UMCG guideline for neonatal
hypoglycemia. All five newborns had normal serum cortisol
levels and USP.
One newborn (patient 11, Table 1) showed a low serum
cortisol level of 80 nmol/L. She did not have hypoglycemia
or hypotension. The USP showed presence of fetal
metabolites. Therefore, dynamic testing of the HPA axis was
not performed.
In two newborns (patients 9 and 16, Table 1), USP from a
urine sample collected on the first day of life showed the
absence of fetal metabolites. Both infants were born pre-term,
did not show hypoglycemia, but did have hypotension during
an episode of clinical sepsis (patient 9 on the 15th day and
patient 16 on the 5th day after birth). They were treated with a
single intravenous fluid bolus with saline and broad-spectrum
antibiotics. They did not receive steroid replacement therapy.
Serum cortisol levels were in the normal range. Within
4 weeks, the USP of both children contained neonatal steroid
hormone metabolites.
Discussion
In this retrospective analysis during a time period of 8 years,
we found 16 live-born children of mothers using ≥10 mg/day
of prednisolone for ≥1 week prior to delivery. The chronic use
of high-dosed prednisolone during pregnancy is thus not of
frequent occurrence. We found no clinical symptoms of adre-
nal suppression, only small abnormalities in the laboratory
results of half of these newborns (eight out of 16) which we
will describe in the following paragraphs.
Five newborns showed hypoglycemia. However, it seems
unlikely that these cases were related to HPA axis suppression
as all had a normal USP and normal serum cortisol levels.
Furthermore, they all had known risk factors for hypoglyce-
mia (e.g., prematurity, birth weight large for gestational age,
and maternal insulin-dependent diabetes gravidarum) and
would therefore have been detected through our local hospital
guideline.
We found one newborn (patient 11) with a low serum cor-
tisol level (80 nmol/L). As newborns do not have a circadian
rhythm of cortisol secretion [4], this finding might have been
the result of taking samples on random moments during the
day. We did not find USP abnormalities or clinical symptoms
suggesting HPA axis suppression in this newborn.
In two newborns (patients 9 and 16), the first USP lacked
fetal metabolites although serum cortisol levels were normal.
During an episode of clinical late-onset sepsis, both newborns
developed hypotension, for which they received a single in-
travenous fluid bolus with saline and broad-spectrum antibi-
otics. They did not receive steroid replacement therapy.
Within 4 weeks after birth, both had USPs containing neonatal
steroid hormone metabolites. Their response to sepsis without
needing steroid replacement therapy suggests that both these
newborns had an adequate adrenal stress response despite a
transient abnormal USP. We can thus conclude that both pre-
terms showed transient abnormal USP without clinical symp-
toms of adrenal insufficiency.













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1134 Eur J Pediatr (2017) 176:1131–1136
Since both these newborns were pre-term (28 and 30 weeks
of gestational age), the immaturity of their HPA axis might
have affected the USP. Furthermore, the enzymatic activity of
11-beta-HSD2 in the placenta could have been decreased be-
cause of immaturity, resulting in a higher transplacental pas-
sage of prednisolone. Indeed, a positive association between
gestational age and 11-beta-HSD2 activity was previously de-
scribed [3].
In both cases, placental bed pathology was suspected
(one mother had hemolysis with elevated liver enzymes
and low platelets (HELLP) syndrome, and the other had
pregnancy-induced hypertension (PIH) combined with
intra-uterine growth restriction). No other cases of placen-
tal bed pathology were found in our database. Placental
bed pathology might influence the function of 11-beta-
HSD2, resulting in a higher (more than double) transpla-
cental passage of prednisolone [5]. However, a more re-
cent study found contrary evidence in women with
HELLP syndrome [10], reporting prednisolone levels of
about 10% of maternal levels in the umbilical cords, sim-
ilar to the levels seen in women without HELLP syn-
drome [6].
Broad reference ranges used in newborn HPA testing
may suggest lack of specificity. Serum cortisol can be
affected by an intrinsic production failure (due to imma-
turity of the HPA axis), as well as extrinsic factors such as
stress during and after delivery [7]. We therefore feel that
the interpretation of normal serum cortisol levels should
take into account the clinical circumstances and the pres-
ence or absence of clinical signs of adrenal insufficiency.
Additional information on the adrenal function can be
provided by USP. Dynamic function testing of the HPA
axis (e.g., ACTH stimulation testing) can confirm adrenal
insufficiency by measuring the adrenal response to stress,
and thus provides the most relevant information for clin-
ical practice. Because our newborns did not show persis-
tent signs of adrenal suppression, dynamic testing of the
HPA axis was not considered necessary.
Study limitations
Although this is the first case series report on the subject,
the most important limitation of our study is the relatively
small number of patients and its retrospective character. It
is possible that the obstetricians and midwives may not
have reported a mother using prednisolone during preg-
nancy and that we might thereby have missed a case. Yet,
all newborns in our region who would have developed
symptomatic adrenal insufficiency would have been ad-
mitted to our NICU.
We found a great heterogeneity in patient characteris-
tics and a wide variation in the dosage of prednisolone
and duration of treatment. Both the small number of
patients and the heterogeneity in patient characteristics
in our study make it difficult to exclude a possible effect
of the use of maternal prednisolone on the neonatal HPA
axis. This uncertainty mainly applies to the different ges-
tational ages of the children. It could be hypothesized that
the influence of maternal prednisolone use on the neonatal
HPA axis is more pronounced when the gestational age of
the infant is younger. A multicenter, prospective cohort
study on a larger number of patients would allow analyses
of sub-groups, e.g., full-term vs. pre-term born infants,
effect of dosage, and duration of prednisolone treatment
and would allow risk factors to be identified using logistic
regression analysis. Such a cohort study would also ben-
efit from dynamic testing of the HPA axis in newborns
showing biochemical evidence of adrenal suppression,
which would allow evaluation of the adrenal response to
stress.
Conclusion
In this retrospective case series of 16 newborns, we found no
evidence of prolonged effects on the neonatal HPA axis of
mothers using prednisolone during pregnancy. Small and tran-
sient biochemical abnormalities were not associated to clinical
symptoms of adrenal insufficiency. However, a prospective
cohort study with a large number of newborns is needed to
further elucidate the effect of maternal corticosteroid use on
the neonatal HPA axis.
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